Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease
Phase of Trial: Phase II/III
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms DIAMOND
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 May 2018 to 1 May 2023.
- 31 Aug 2018 Biomarkers information updated